Process for preparing zanubrutinib
By not isolating the intermediate compound of formula (II) and controlling the reaction conditions, the synthesis process for Zanubrutinib minimizes impurity formation, ensuring the product meets specifications and is suitable for industrial production.
Patent Information
- Application Number
- PCT/IB2023/061735
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-24
- Filing Date
- 2023-11-21
- Publication Date
- 2024-11-28
AI Technical Summary
The existing synthesis process for Zanubrutinib involves the use of anti-solvents that cause unwanted impurities, making it difficult to meet the required specifications for the final product, particularly due to the reaction of the intermediate compound of formula (II) with these solvents, leading to out-of-specification products.
The process avoids isolating the intermediate compound of formula (II) from the reaction medium, eliminating the need for anti-solvents, and instead, uses a series of reactions involving methanesulfonic acid, an aqueous medium, and a base to control pH, followed by conversion to a salt and subsequent reaction with acryloyl chloride to produce Zanubrutinib, which can be in crystalline or amorphous form, thereby minimizing impurity formation.
This approach effectively reduces impurity formation, ensuring the final product meets the required specifications by avoiding interactions with anti-solvents, thus enhancing the stability and purity of Zanubrutinib, suitable for industrial scale-up.
Smart Images

Figure IB2023061735_28112024_PF_FP_ABST
Abstract
Description
[0001] "Process for preparing Zanubrutinib"
[0002] The present invention relates to a process for preparing Zanubrutinib .
[0003] Zanubrutinib is an active principle classified as a Bruton tyrosine kinase (BTK) inhibitor, currently approved by the Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one previous therapy. It is marketed under the name Brukinsa®.
[0004] WO 2014 / 173289, in the name of Beigene LTD, describes Zanubrutinib and its preparation (compound 27) .
[0005] The Zanubrutinib synthesis process is also described in WO 2018 / 033135 (WO' 135) . This process involves, among other steps, synthesis and isolation of an intermediate compound of formula (II) : formula II from an intermediate compound of formula (I) : formula I where X is Cl. In this regard, see Step 13 on p. 36 of WO' 135, where the compound of formula (II) is identified by the abbreviation BG-12 and the compound of formula (I) by the abbreviation BG-11C. As can be seen from this example, at the end of Step 13, the compound of formula (II) was separated from the organic phase and isolated using methyl-t-butyl ether (MTBE) and n-heptane as anti-solvents causing its precipitation. The compound of formula (II) is indeed difficult to crystallise by cooling, so its isolation by crystallisation requires the use of anti-solvents.
[0006] However, the Applicant has found that the compound of formula (II) has a tendency to react with anti-solvents, such as those used in WO' 135, forming impurities that are difficult to remove. Thus, the compound of formula (II) , when isolated as described in WO' 135, has a certain amount of impurities, which are also found in the final product Zanubrutinib, often in quantities that do not meet the required specifications for this active principle.
[0007] Therefore, there is a need to find a process for the preparation of Zanubrutinib that will control the formation of unwanted by-products and is suitable for industrial scale-up.
[0008] The Applicant has found that this technical problem, and others that will be highlighted below, can be solved by a process for preparing Zanubrutinib, in which the intermediate of formula (II) is not isolated from the reaction medium, so there is no need to use anti-solvents that may compromise the stability of the compound of formula (II) and generate unwanted by-products .
[0009] Therefore, according to a first aspect, the present invention concerns a process for preparing Zanubrutinib of formula A:
[0010] which comprises:
[0011] (a) reacting a compound of formula I: formula I wherein X is a halogen, preferably chlorine, with methanesulfonic acid (MsOH) , to obtain a compound of formula formula II
[0012] (b) adding an aqueous medium to the reaction mixture obtained from step (a) ;
[0013] (c) adding a base to the mixture obtained from step (b) up to obtain a pH higher than 8, preferably from 11 to 12; (d) optionally converting the compound of formula II into a salt thereof by reaction with an acid, preferably with an organic acid;
[0014] (e) converting the compound of formula II, or the salt thereof, to Zanubrutinib; wherein the compound of formula II obtained from step (a) is not isolated.
[0015] Preferably, the aqueous medium is water, or a mixture of water and a water-soluble organic solvent, e.g. an alcohol, particularly methyl alcohol or ethyl alcohol.
[0016] In the event that the compound of formula II is converted to a salt thereof according to step (d) , the compound of formula II is preferably reacted with an acid selected from: L-DBTA acid (L-dibenzoyltartaric) , D-DBTA (D- dibenzoyltartaric) , L-DTTA (di-p-toluyl-L-tartaric acid) , D- DTTA (di-p-toluyl-D-tartaric acid) , L-malic acid, D-malic acid, L-mandelic acid, D-mandelic acid, L-camphorsulphonic acid, D-camphorsulphonic acid, L-tartaric acid, D-tartaric acid. The salt of the compound of formula II with L-DBTA is particularly preferred.
[0017] Preferably, the molar ratio between acid and compound of formula II is from 1:2 to 1:1, more preferably the molar ratio is 1:2.
[0018] Preferably, step (e) , in which the compound of formula II, or a salt thereof, is converted to Zanubrutinib, is achieved by reacting the compound of formula II, or a salt thereof, with acryloyl chloride.
[0019] The Zanubrutinib obtained from step (e) can be in crystalline or amorphous form.
[0020] Preferably, to obtain Zanubrutinib in amorphous form, the Zanubrutinib obtained from step (e) is reacted with a coformer selected from 3-hydroxybenzoic acid, 2 , 4-dihydroxybenzoic acid, 4-aminobenzoic acid and 4-methylaminobenzoic acid, to obtain Zanubrutinib co-crystal . The Zanubrutinib co-crystal i s then converted to amorphous Zanubrutinib .
[0021] Preferably, the conversion of Zanubrutinib co-crystal to amorphous Zanubrutinib occurs by treatment of the co-crystal in water at controlled pH, preferably at basic pH . Preferably the pH is greater than or equal to 9 . Preferably the pH is from 9 to 12 . The conversion step allows the precipitation of amorphous Zanubrutinib .
[0022] Advantageously, the process according to the present invention avoids the formation of impurities from the interaction of the compound of formula I T with the antisolvents used for the crystallisation thereof .
[0023] In particular, the process o f the invention makes it possible to avoid, or in any event to control , the formation of the following impurities :
[0024] The impurity of formula I T T , which is formed by the addition of MTBE to the product of formula I I , is particularly critical , as it remains in the finished product even after sequential crystallisation .
[0025] The Applicant has veri fied that , by following the procedure for isolation of the compound of formula I I according to the aforementioned WO ' 135 , a final product is obtained with a high content of impurities , such that it risks exceeding the limits allowed for the active principle to meet the required specifications, as demonstrated by the data in Table 1 below, relating to the synthesis of Zanubrutinib according to WO' 135: Table 1 Therefore, the use of an anti-solvent to crystallise and isolate the compound of formula II, in particular MTBE according to WO' 135, represents a real risk that may lead to the production of an out-of-specification product.
[0026] The following embodiment examples are provided merely to illustrate the present invention and should not be construed so as to limit the scope of protection defined by the claims.
[0027] Example 1 - Synthesis of compound of formula II (in salt form with L-DBTA) . un composto di formula II
[0028] The compound of formula I (10 g, 21.17 mmol) and methanesulphonic acid (25 ml) were loaded into a flask. The reaction was heated to 85°C for 5 hours. When the reaction was complete, the solution was cooled to -5°C. Water (40 ml) was slowly dripped in, keeping the temperature less than or equal to 25°C. The reaction was raised to 30°C for 16 hours. Dichloromethane (60 ml) was added and the solution was cooled to -5°C. A solution of 30% NaOH (55 ml) and demineralised water (25 ml) was prepared and cooled to 5°C. The basic solution was slowly dripped into the reaction while maintaining the temperature less than or equal to 5°C (internal) , until a pH between 11 and 12 was reached. The mixture was brought back to 20°C and left to stir for 10 minutes. The organic phase was separated from the aqueous phase, which was then re-extracted with dichloromethane (50 ml) . The organic phases were combined and concentrated to a residual volume of 50 ml. Demineralised water (50 ml) was added to the solution. The solution was concentrated under reduced pressure to a residual volume of 50 ml. Methanol (100 ml) was slowly added and the solution was heated to 30°C. A solution consisting of L-DBTA monohydrate (4.38 g, 11.64 mmol) and methanol (50 ml) was prepared in another flask. The solution was stirred at 25°C until complete dissolution of the product.
[0029] While maintaining the temperature at 30°C, L-DBTA acid was added to the solution from the work-up. The solution was kept stirring for 16 hours at 30°C. The reaction mixture was cooled to a temperature comprised between 0°C and 5°C and so maintained for approximately 2 hours. The mixture was filtered through a Buchner filter, washing with a few ml of methanol at the end. Approximately 10 g of moist white solid was discharged. The product was dried at a temperature comprised between 45°C and 55°C for at least 12 hours. 8 g of dry white product was discharged, with a molar yield of 64%.
[0030] Figure 1 shows the hydrogen nuclear magnetic resonance spectrum (1H-NMR) of the compound of formula IT thus obtained (in salt form with L-DBTA) (spectrum obtained with NMR300 Mercury 300 spectrometer, at 25°C, with solvent D2O) .
[0031] Example 2 - Synthesis of co-crystal Zanubrutinib .
[0032] 2.84 g (4.79 mmol) of the compound of formula II in salt form with L-DBTA, obtained from Example 1, were loaded into a flask with acetonitrile (28 ml) and demineralised water (14 ml) . The suspension was stirred and NaOH 30% aq (1.5 eq, 0.958 g) was slowly loaded. Stirring was continued for 15 minutes. Ethyl acetate was loaded (17 ml) and the phases were separated. The organic phase was washed with NaCl 15% aq., and the final organic phase was concentrated to produce 10 ml residue. 30 ml of acetonitrile was loaded and concentration was carried out up to 24 ml residue. Demineralised water (25 ml) , NaHCCh 1.2 g (3 eq) and L-tartaric acid 358 mg (0.5 eq) were then loaded into the flask. The temperature was raised to -2°C and acryloyl chloride (564 mg, 1.3 eq) was dripped. After 15 minutes, isopropyl acetate (12 ml) was added and the phases were separated. The organic phase was washed with 5 % NaHCCh aq. and isopropyl acetate (40 ml) and the coformer selected from 3-hydroxybenzoic acid (1.1 eq) were loaded onto the organic phase .
[0033] The organic phase was concentrated to a small volume then more isopropyl acetate was added until the acetonitrile was removed. The final solution was brought to 40°C and triggered. When abundant precipitate was observed, it was filtered and washed with 2 ml isopropyl acetate. The co-crystal was dried in a vacuum oven at 45°C for 6 hours.
[0034] Example 3 - Synthesis of amorphous Zanubrutinib.
[0035] The co-crystal Zanubrutinib obtained from Example 2 (2 g) and DMSO (6 ml) were loaded into a flask. The mixture was stirred until completely dissolved. A 70 ml solution of NaHCCh 5% aq. was prepared in another flask and the DMSO solution was slowly dripped onto the aqueous solution, while maintaining vigorous stirring . The suspension was left stirring for 1 hour , then filtered and washed with water . The solid was discharged and dissolved in 6 ml of DMSO . A 70 ml solution of NaHCCh 5% aq . was prepared in another flask and the DMSO solution was slowly dripped onto the aqueous solution, while maintaining vigorous stirring . The suspension was stirred for 1 hour, then filtered and washed with water . The solid was discharged and washed with 2 slurries in water for 1 hour each . The final amorphous solid was dried in an oven at 35 ° C for 16 hours .
Claims
CLAIMS1. Process for preparing Zanubrutinib of formula A:formula A which comprises:(a) reacting a compound of formula I:formula I whereinIS a halogen, preferably chlorine, with me thane sulfonic acid (MsOH) , to obtain a compound of formulaII :formula II(b) adding an aqueous medium to the reaction mixture obtained from step (a) ;(c) adding a base to the mixture obtained from step (b) until obtaining a pH higher than 8, preferably from 11 to 12;(d) optionally converting the compound of formula II into a salt thereof by reaction with an acid, preferably with an organic acid;(e) converting the compound of formula II, or the salt thereof, to zanubrutinib; wherein the compound of formula II obtained from step (a) is not isolated.
2. The process according to claim 1, wherein the aqueous medium is water, or a mixture of water and a water-soluble organic solvent.
3. The process according to claim 2, wherein the water- soluble organic solvent is an alcohol, preferably methyl alcohol or ethyl alcohol.
4. The process according to any one of the preceding claims, wherein step (d) of converting the compound of formula II into a salt thereof is carried out by reaction of the compound of formula II with an acid selected from: L-DBTA acid (L-dibenzoyltartaric) , D-DBTA (D-dibenzoyltartaric) , L-DTTA (Di-p-toluyl-L-tartaric acid) , D-DTTA (Di-p-toluyl-D-tartaric acid) , L-malic acid, D-malic acid, L-mandelic acid, D-mandelic acid, L-camphorsulphonic acid, D-camphorsulphonic acid, L- tartaric acid, D-tartaric acid.
5. The process according to claim 4, wherein the ratio by weight of acid to compound of formula II is from 1:2 to 1:1, preferably the ratio is 1:2.
6. The process according to any one of the preceding claims, wherein step (e) is carried out by reacting the compound of formula II, or a salt thereof, with acryloyl chloride .. The process according to any one of the preceding claims , wherein the Zanubrutinib obtained from step ( e ) is in crystalline form or in amorphous form .8 . The process according to any one of the preceding claims , wherein, to obtain Zanubrutinib in amorphous form, the Zanubrutinib obtained from step ( e ) is reacted with a coformer selected from : 3-hydroxybenzoic acid, 2 , 4-dihydroxybenzoic acid , 4-aminobenzoic acid and 4-methylaminobenzoic acid, to obtain Zanubrutinib co-crystal ; and then the co-crystal zanubrutinib is converted to amorphous zanubrutinib .9 . The process according to claim 8 , wherein the Zanubrutinib co-crystal is converted into Zanubrutinib in amorphous form by treating the Zanubrutinib co-crystal in water with a basic pH, preferably greater than or equal to 9 .10 . The process according to claim 9 , wherein the pH i s from 9 to 12 .
